Patents by Inventor Tomoko Ashizawa

Tomoko Ashizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL AMINO ACID DERIVATIVES
    Publication number: 20230312479
    Abstract: A novel amino acid derivative is provided, wherein the amino acid derivative is expected to improve binding affinity of polypeptides comprising the derivative therein.
    Type: Application
    Filed: March 28, 2023
    Publication date: October 5, 2023
    Inventors: Haruaki Kurasaki, Masatoshi Matsumoto, Ayumu Matsuda, Yutaka Kobayashi, Masahiko Kinebuchi, Tomoko Ashizawa, Katsuma Matsui, Motoki Murai, Masami Yamada
  • NOVEL AMINO ACID DERIVATIVES
    Publication number: 20230257343
    Abstract: A novel amino acid derivative is provided, wherein the amino acid derivative is expected to improve solubility of polypeptides comprising the derivative therein.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 17, 2023
    Inventors: Naoki OKADA, Kyosuke UEDA, Masatoshi TAKUWA, Shunichi NAKANO, Kotaro TOKUMOTO, Tomoko ASHIZAWA, Shuhei YAMAKOSHI, Yutaka KOBAYASHI, Katsuma MATSUI, Ayumu MATSUDA, Masatoshi MATSUMOTO, Keiichi MASUYA, Atsushi YOSHIZAWA, Masahiko KINEBUCHI, Takeru EHARA, Masami YAMADA, Kouki MORIMOTO, Yoshihide MIZUKOSHI, Haruaki KURASAKI, Motoki MURAI, Kentarou FUKUMOTO, Douglas Robert CARY
  • Nitrogen-containing heterocyclic compound
    Patent number: 10214508
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 26, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Tomoko Ashizawa, Toshihiro Imaeda, Ikuo Fujimori, Ryosuke Arai
  • Nitrogenated heterocyclic compound
    Patent number: 10017508
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: July 10, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki
  • NITROGENATED HETEROCYCLIC COMPOUND
    Publication number: 20170129887
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 13, 2016
    Publication date: May 11, 2017
    Inventors: Satoshi MIKAMI, Shinji NAKAMURA, Tomoko ASHIZAWA, Shigekazu SASAKI, Takahiko TANIGUCHI, Izumi NOMURA, Masanori KAWASAKI
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20170121308
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Tomoko ASHIZAWA, Toshihiro IMAEDA, Ikuo FUJIMORI, Ryosuke ARAI
  • Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
    Patent number: 9527841
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: December 27, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Kawasaki Masanori, Izumi Nomura, Tomoko Ashizawa, Takahiko Taniguchi
  • Nitrogenated heterocyclic compound
    Patent number: 9469637
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: October 18, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20160264536
    Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 15, 2016
    Inventors: Masaki SETO, Yoshihiro BANNO, Toshihiro IMAEDA, Yuichi KAJITA, Tomoko ASHIZAWA, Masanori KAWASAKI, Shinji NAKAMURA, Satoshi MIKAMI, Izumi NOMURA, Takahiko TANIGUCHI, Shogo MARUI
  • HETEROCYCLIC COMPOUND
    Publication number: 20160159808
    Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 9, 2016
    Inventors: Masanori Kawasaki, Satoshi Mikami, Shinji Nakamura, Nobuyuki Negoro, Shuhei Ikeda, Izumi Nomura, Tomoko Ashizawa, Toshihiro Imaeda, Masaki Seto, Shigekazu Sasaki, Shogo Marui, Takahiko Taniguchi
  • HETEROCYCLIC COMPOUND
    Publication number: 20150158863
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 11, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Kawasaki Masanori, Izumi Nomura, Tomoko Ashizawa, Takahiko Taniguchi
  • NITROGENATED HETEROCYCLIC COMPOUND
    Publication number: 20150105373
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 16, 2015
    Inventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki